Evidence map›Paper›PMID 22500168›Full record

ArticleAdvances in virology2012

Advances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated Malignancies.

Sajal K Ghosh, Susan P Perrine, Douglas V Faller

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in virology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma.Journal of cancer research and clinical oncology · 2015
    Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. [Research progress on targeted therapies of Epstein-Barr virus-associated lymphomas].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019
    Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Viral Oncology: Molecular Biology and Pathogenesis.Journal of clinical medicine · 2017
    Review
  16. [Aggressive primary cutaneous B-cell lymphomas and novel EBV+ entities].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2017
    Review
  17. Article
  18. Article
  19. Review
  20. Icaritin induces lytic cytotoxicity in extranodal NK/T-cell lymphoma.Journal of experimental & clinical cancer research : CR · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sajal K GhoshCancer Center, Boston University School of Medicine, Boston, MA 02118, USA.
Susan P Perrine
Douglas V Faller

Funding

Virus-targeted therapeutic for EBV-Associated MalignanciesR44CA153474 · NCI · PHOENICIA BIOSCIENCES, INC. · PI PERRINE, SUSAN PARK · 2016 to 2017
$992k
Virus-Targeted Therapy for MalignanciesR43CA153474 · NCI · PHOENICIA BIOSCIENCES, INC. · PI PERRINE, SUSAN PARK · 2011 to 2011
$289k
NCI NIH HHS R43 CA153474NCI NIH HHS R44 CA153474
6 · The paper itself

Abstract

Epstein-Barr virus (EBV) is the causal agent in the etiology of Burkitt's lymphoma and nasopharyngeal carcinoma and is also associated with multiple human malignancies, including Hodgkin's and non-Hodgkin's lymphoma, and posttransplantation lymphoproliferative disease, as well as sporadic cancers of other tissues. A causal relationship of EBV to these latter malignancies remains controversial, although the episomic EBV genome in most of these cancers is clonal, suggesting infection very early in the development of the tumor and a possible role for EBV in the genesis of these diseases. Furthermore, the prognosis of these tumors is invariably poor when EBV is present, compared to their EBV-negative counterparts. The physical presence of EBV in these tumors represents a potential "tumor-specific" target for therapeutic approaches. While treatment options for other types of herpesvirus infections have evolved and improved over the last two decades, however, therapies directed at EBV have lagged. A major constraint to pharmacological intervention is the shift from lytic infection to a latent pattern of gene expression, which persists in those tumors associated with the virus. In this paper we provide a brief account of new virus-targeted therapeutic approaches against EBV-associated malignancies.

Identifiers

PMID22500168
PMCPMC3303631

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.